Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunosyn signs amended license agreement
The amended license agreement expands the grant of rights to Immunosyn to include the exclusive worldwide right to market, sell, distribute and promote SF-1019 in its current form
The amended license agreement expands the grant of rights to Immunosyn to include the exclusive worldwide right to market, sell, distribute and promote SF-1019 in its current form
Aradigm’s randomized, open-label, single-site Phase I trial evaluated arterial plasma pharmacokinetics and subjective acute cigarette craving when one of three nicotine doses (0.2mg, 0.4mg and 0.7mg) was administered
MedaSorb’s commercialization plan calls for CytoSorb to first enter the market in Europe and then in the US, followed by its pipeline of additional products. MedaSorb is initiating
The QuantRx biomedical female fertility test is a one-step lateral flow device that determines ovarian reserve indirectly by measuring follicle stimulating hormone (FSH) in first morning urine. The
NKTR-102 (Peg-irinotecan) is a pegylated form of irinotecan developed using Nektar’s innovative small molecule pegylation technology platform. NKTR-102 inhibited tumor growth by greater than 90% in mouse xenograft
Meda also obtains product rights, trademarks and right to the Recip name. Recipharm will continue as a contract manufacturer for Meda and is not part of the deal.
The Clinical Research Center of Cape Cod (CRCCC) is a medical research firm with products and services that support the pharmaceutical, biotechnology, diagnostic and genomics industries. John Cousins,
Pharmacokinetic results demonstrate that once-a-day orally-administered antimitotic agent ENMD-1198 has good pharmacokinetic (PK) parameters in cancer patients participating in a Phase I clinical study. In the first four
The Juvenile Diabetes Research Foundation has provided $4 million in funding to support the development of Prochymal. The trial will evaluate the safety and efficacy of Prochymal in
As a result, NPS will receive a milestone payment plus royalties from Kirin Pharma, a wholly-owned subsidiary of Kirin Holdings, which will market the drug in Japan. Kirin